Recombinant Human SUMO3/SMT3A Protein (aa 2-92, His Tag)

Catalog Number: PKSH033069

Note: *Centrifuge before opening to ensure complete recovery of vial contents.*

Description

Species	Human
Source	HEK293 Cells-derived Human SUMO3;SMT3A protein Ser2-Gly92, with an C-terminal His
Calculated MW	11.1 kDa
Observed MW	20 kDa
Accession	P55854
Bio-activity	Not validated for activity

Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 ℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Small ubiquitin-like modifier (SUMO); also known as SUMO homologue and SMT3; is a member of the superfamily of ubiquitin-like polypeptides that become covalently attached to various intracellular target proteins as a way to alter their function; location; and/or half-life. Small ubiquitin-like modifiers include SUMO1; SUMO2; SUMO3; and SUMO4. Except for SUMO4; all other SUMOs are ubiquitously expressed; including in the brain. In human; SUMO2 and SUMO3 are two highly homologous proteins; collectively called SUMO2/3. Several studies suggest that SUMO3 are associated with pathogenesis in several neurological diseases; including Alzheimer's disease; Parkinson's disease; and cerebral ischemia/stroke.

For Research Use Only